Tumor physiology and charge dynamics of anticancer drugs: Implications for camptothecin-based drug development

Current Medicinal Chemistry

Volumn 18, Issue 9, 2011, Pages 1367-1372

  Adams, D J ^a,b   Morgan, L R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DEKK TEC Incorporated   (United States)

Author keywords

Camptothecin; Charge dynamics; Glycolytic phenotype; Hypoxia; PKa; Topoisomerase I; Tumor pH gradient

Indexed keywords

7 BUTYL 10 AMINOCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CARBOXYLIC ACID; COSITECAN; DNA TOPOISOMERASE; GIMATECAN; IRINOTECAN; LACTONE; LACTONE DERIVATIVE; MITOCHONDRIAL ENZYME; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ARTICLE; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CELL MEMBRANE PERMEABILITY; CHEMICAL REACTION KINETICS; COMPUTER MODEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; HUMAN; HYPOXEMIA; IONIZATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PH; PHARMACOKINETICS; PHENOTYPE; PKA; PREDICTION; TISSUE DISTRIBUTION; TUMOR;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; HUMANS; KINETICS; NEOPLASMS; TOPOISOMERASE I INHIBITORS;

EID: 79952784195     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029609     Document Type: Article

References (35)

1. Prankerd, R. Critical compilation of pKa values for pharmaceutical substances. Elsevier Academic Press: San Diego, 2007.
2. Atkuri, K.R.; Herzenberg, L.A. Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(10), 3756-3759. (Pubitemid 40354684)
3. Ivanovic, Z. Hypoxia or In Situ Normoxia: The Stem Cell Paradigm. J. Cell. Physiol., 2009, 219(2), 271-275.
4. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3(10), 721-732. (Pubitemid 37328811)
5. Pencreach, E.; Guerin, E.; Nicolet, C.; Lelong-Rebel, I.; Voegeli, A.C.; Oudet, P.; Larsen, A.K.; Gaub, M.P.; Guenot, D. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1 alpha axis. Clin. Cancer Res., 2009, 15(4), 1297-1307.
6. Talks, K.L.; Turley, H.; Gatter, K.C.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 2000, 157(2), 411-421. (Pubitemid 30626905)
7. Stubbs, M.; Bashford, C.L.; Griffiths, J.R. Understanding the tumor metabolic phenotype in the genomic era. Curr. Mol. Med., 2003, 3(1), 49-59. (Pubitemid 36131677)
8. Gatenby, R.A.; Gawlinski, E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: Insights through mathematical models. Cancer Res., 2003, 63(14), 3847-3854. (Pubitemid 36917892)
9. Gillies, R.J.; Robey, I.; Gatenby, R.A. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med., 2008, 49, 24S-42S. (Pubitemid 351948035)
10. Kim, J.W.; Dang, C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res., 2006, 66(18), 8927-8930. (Pubitemid 44521105)
11. Robey, I.F.; Lien, A.D.; Welsh, S.J.; Baggett, B.K.; Gillies, R.J. Hypoxiainducible factor-1 alpha and the glycolytic phenotype in tumors. Neoplasia, 2005, 7(4), 324-330. (Pubitemid 40664221)
12. Warburg, O. The Metabolism of Tumours. Biochem. Z., 1923, 142, 317.
13. Warburg, O. On respiratory impaiment in cancer cells: Reply. Science, 1956, 124(3215), 269-270.
14. Gerweck, L.E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res., 1996, 56(6), 1194-1198. (Pubitemid 26080953)
15. Mahoney, B.P.; Raghunand, N.; Baggett, B.; Gillies, R.J. Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol., 2003, 66(7), 1207-1218. (Pubitemid 37130296)
16. Raghunand, N.; Mahoney, B.P.; Gillies, R.J. Tumor acidity, ion trapping and chemotherapeutics I. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem. Pharmacol., 2003, 66(7), 1219-1229. (Pubitemid 37130297)
17. Gerweck, L.E.; Kozin, S.V.; Stocks, S.J. The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br. J. Cancer, 1999, 79(5-6), 838-842. (Pubitemid 29082114)
18. Adams, D.J.; Dewhirst, M.W.; Flowers, J.L.; Gamcsik, M.P.; Colvin, O.M.; Manikumar, G.; Wani, M.C.; Wall, M.E. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother. Pharmacol., 2000, 46(4), 263-271.
19. Gerweck, L.E.; Vijayappa, S.; Kozin, S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther., 2006, 5(5), 1275-1279. (Pubitemid 43881320)
20. Jacobs, M. Some aspects of cell permeability to weak electrolytes. Cold Spring Harbor Symp Quant Biol, 1940, 8, 30-39.
21. Liao, C.Z.; Nicklaus, M.C. Comparison of nine programs predicting pK(a) values of pharmaceutical substances. J. Chem. Inform. Model., 2009, 49(12), 2801-2812.
22. Manchester, J.; Walkup, G.; Rivin, O.; You, Z.P. Evaluation of pK(a) estimation methods on 211 drug like compounds. J. Chem. Inform. Model., 2010, 50(4), 565-571.
23. Meloun, M.; Bordovska, S. Benchmarking and validating algorithms that estimate pK(a) values of drugs based on their molecular structures. Anal. Bioanal. Chem., 2007, 389(4), 1267-1281. (Pubitemid 47482274)
24. Adams, D.J. The impact of tumor physiology on camptothecin-based drug development. Curr. Pharm. Med. Chem.-Anticancer Agents, 2005, 5(1), 1-13. (Pubitemid 40081290)
25. Mellor, H.R.; Callaghan, R. Resistance to chemotherapy in cancer: A complex and integrated cellular response. Pharmacology, 2008, 81(4), 275-300. (Pubitemid 351666917)
26. Meloun, M.; Bordovska, S.; Vrana, A. The thermodynamic dissociation constants of the anticancer drugs camptothecine, 7-ethyl-10- hydroxycamptothecine, 10-hydroxycamptothecine and 7-ethylcamptothecine by the least-squares nonlinear regression of multiwavelength spectrophotometric pH-titration data. Anal. Chim. Acta, 2007, 584(2), 419-432. (Pubitemid 46172446)
27. Adams, D.J.; Wahl, M.L.; Flowers, J.L.; Sen, B.; Colvin, M.; Dewhirst, M.W.; Manikumar, G.; Wani, M.C. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother. Pharmacol., 2006, 57(2), 145-154. (Pubitemid 41779833)
28. Adams, D.; Waud, W.; Wani, M.; Manikumar, G.; Flowers, J.; Driscoll, T.; Morgan, L. BACPTDP: A water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. Cancer Chemother. Pharmacol., 2010, Online First(22 June).
29. Chourpa, I.; Millot, J.M.; Sockalingum, G.D.; Riou, J.F.; Manfait, M. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochimica Et Biophysica Acta- General Subjects, 1998, 1379(3), 353-366. (Pubitemid 28127878)
30. Burke, T.G.; Mi, Z.H. Preferential binding of the carboxylate form of camptothecin by human serum-albumin. Anal. Biochem., 1993, 212(1), 285-287. (Pubitemid 23219487)
31. Burke, T.G.; Munshi, C.B.; Mi, Z.H.; Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci., 1995, 84(4), 518-519.
32. Hsiang, Y.H.; Liu, L.F.; Wall, M.E.; Wani, M.C.; Nicholas, A.W.; Manikumar, G.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cyto-toxicity of camptothecin analogs. Cancer Res., 1989, 49(16), 4385-4389. (Pubitemid 19208330)
33. de la Loza, M.C.D.; Wellinger, R.E. A novel approach for organelle-specific DNA damage targeting reveals different susceptibility of mitochondrial DNA to the anticancer drugs camptothecin and topotecan. Nucleic Acids Res., 2009, 37(4).
34. Zhang, H.L.; Barcelo, J.M.; Lee, B.; Kohlhagen, G.; Zimonjic, D.B.; Popescu, N.C.; Pommier, Y. Human mitochondrial topoisomerase I. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(19), 10608-10613. (Pubitemid 32878668)
35. Raghunand, N.; Gillies, R.J. pH and drug resistance in tumors. Drug Resistance Updates, 2000, 3(1), 39-47. (Pubitemid 30246567)